Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis

Hepatology

Volumn 44, Issue 2, 2006, Pages 399-409

  Descamps, Delphyne ^a   Vigant, Frédéric ^a   Esselin, Stéphanie ^a   Connault, Elisabeth ^a   Opolon, Paule ^a   Perricaudet, Michel ^a   Benihoud, Karim ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; DEATH RECEPTOR; FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CELL DEATH; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HEPATITIS; HUMAN; HUMAN CELL; HYDRODYNAMICS; LIVER; LIVER CELL DAMAGE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK; T LYMPHOCYTE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; GENE EXPRESSION; HEPATITIS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 33747055072     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21257     Document Type: Article

References (49)

1. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004;21:461-465.
2. Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 2003;15:167-176.
3. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-372.
4. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354-2357.
5. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000;288:2351-2354.
6. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A 2005;102:18099-18104.
7. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003;15:325-331.
8. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-413.
9. Spooner CE, Markowitz NP, Saravolatz LD. The role of tumor necrosis factor in sepsis. Clin Immunol Immunopathol 1992;62:S11-S17.
10. Martinez OM, Krams SM. Involvement of Fas-Fas ligand interactions in graft rejection. Int Rev Immunol 1999;18:527-546.
11. Eichhorst ST, Krueger A, Muerkoster S, Fas SC, Golks A, Gruetzner U, et al. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 2004;10:602-609.
12. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-867.
13. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
14. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-4055.
15. Pittet D, Harbarth S, Suter PM, Reinhart K, Leighton A, Barker C, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med 1999;160:852-857.
16. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-371.
17. Deng GM, Zheng L, Chan FK, Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005;11:1066-1072.
18. Keystone EC. Safety of biologic therapies: an update. J Rheumatol (Suppl) 2005;74:8-12.
19. Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 2003;100:7797-7802.
20. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
21. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-839.
22. Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion: relevance to the pathophysiology of septic shock. J Clin Invest 1998;101:650-659.
23. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-36.
24. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-1213.
25. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703.
26. Jenkins M, Keir M, McCune JM. A membrane-bound Fas decoy receptor expressed by human thymocytes. J Biol Chem 2000;275:7988-7993.
27. Mullan B, Dugue C, Moutard V, Raoux D, Tremp G, Denefle P, et al. Robust functional gene validation by adenoviral vectors: one-step Escherichia coli-derived recombinant adenoviral genome construction. Gene Ther 2004;11:1599-1605.
28. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A 1998;95:6367-6372.
29. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996;7:215-222.
30. Liu D, Knapp JE. Hydrodynamics-based gene delivery. Curr Opin Mol Ther 2001;3:192-197.
31. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
32. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992;90:196-203.
33. Lehmann V, Freudenberg MA, Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J Exp Med 1987;165:657-663.
34. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179.
35. Dimakou K, Papaioannides D, Latsi P, Katsimboula S, Korantzopoulos P, Orphanidou D. Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int J Clin Pract 2004;58:1052-1055.
36. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004;28:67-74.
37. Yokota A, Takeuchi E, Iizuka M, Ikegami Y, Takayama H, Shinohara N. Prominent dominant negative effect of a mutant Fas molecule lacking death domain on cell-mediated induction of apoptosis. Mol Immunol 2005;42:71-78.
38. Legembre P, Barnhart BC, Zheng L, Vijayan S, Straus SE, Puck J, et al. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep 2004;5:1084-1089.
39. Fielding CA, Siebert S, Rowe M, Brennan P. Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. FEBS Lett 2004;570:138-142.
40. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15:1157-1166.
41. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994;1:433-442.
42. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-1266.
43. Zhang G, Song YK, Liu D. Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther 2000;7:1344-1349.
44. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004;11:675-682.
45. Zhang X, Dong X, Sawyer GJ, Collins L, Fahre JW. Regional hydrodynamic gene delivery to the rat liver with physiological volumes of DNA solution. J Gene Med 2004;6:693-703.
46. Wesche-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005;106:2295-2301.
47. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178.
48. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-378.
49. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004;20:521-524.